Please check back with us for the latest news, announcements, and updates at Park Allergy Center!
Association Between COVID-19 Vaccination and Neuropsychiatric Conditions James A Thorp, MD 1, Claire Rogers, MSPAS, PA-C *2, Kirstin Cosgrove, CCRA 3 Steven Hatfill, MD M Med 4, Peter Breggin, MD 5, Drew Pinsky, MD 6, Peter A McCullough, MD, MPH 7
This study collected data from the CDC, FDA and VAERS database from 1990 through 2024. It was published in June 2025. Its findings are alarming to say the least. It used Proportional Reporting Ratios (PRRs) to compare numbers of Adverse Events reports after COVID shots with reports after influenza vaccinations and total vaccinations. A PRR of 1 means the number of reports were equal with both drugs. A PRR of 2 means there were twice as many reports in the study drug compared to the comparison drug. The CDC and FDA define a PRR of 2 or greater as the safety threshold to investigate a potential danger in the study drug.
ALL of the following Adverse Events had a PRR of far greater than 2. As you can see, many were greater than 100 (100 times as many reports compared to the comparison drug).
Multiple other studies have demonstrated the same catastrophic results.
https://pubmed.ncbi.nlm.nih.gov/39560882
https://pubmed.ncbi.nlm.nih.gov/38806183
https://pubmed.ncbi.nlm.nih.gov/38834668
Yes, COVID was a stressful time. But stress is not the primary reason our neurologists, psychiatrists, and psychologists have been so busy these past 5 years…
COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes Claire Rogers 1,*, James A Thorp 2,3, Kirstin Cosgrove 4 and Peter A McCullough 5
https://www.ijirms.in/index.php/ijirms/article/view/1982
This study used data from CDC, FDA, and VAERS databases from 1990 through 2023. It compared reports of Adverse Events after COVID shots compared to those after influenza vaccines and to all other vaccines. It did this by using Proportional Reporting Ratio (PRR). PRRs are a statistical measure to help detect whether a specific adverse event from one drug is reported more often compared to another. It is commonly used to identify potential safety signals. A PRR of 1 means the Adverse Event was reported at the same rate for both drugs. A PRR of 2 means the Adverse Event was reported twice as often in the subject drug compared to the comparison drug. Indeed, a PRR of 2 is the usual cut off to trigger a safety signal.
Cerebral Venous Thrombosis was reported 2000 times more often after COVID shots compared to influenza vaccinations (PRR 2070: 95% CI, 955-4490, p < 0.0001).
Cerebral Arterial Thrombosis was reported 1000 times more often after COVID shots compared to influenza vaccinations (PRR 1120: 95% CI, 152-8280, p < 0.0001).
Total Cerebral Thrombosis was reported 1000 times more often after COVID shots compared to influenza vaccinations (PRR 1120: 95% CI, 723-1730, p < 0.0001).
Atrial fibrillation was reported 100 times more often after COVID shots compared to all other vaccines (PRR 123: (95% CI, 88.3-172, p << 0.0001).
Further, the “Pfizer post-marketing analysis done from December 10, 2020 to February 28, 2021 [documented] 42,086 casualties including 1223 deaths in just the first 10 weeks of rollout.”*
*BNT162b2 5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021. Report prepared by Worldwide Safety Pfizer for the Federal Drug Administration and approved on April 30, 2021.https://phmpt.org/wp- content/uploads/2021/11/5.3.6-postmarketing-experience.pdf. (Accessed June 15, 2023).
By the way, this 10 week analysis is part of the Pfizer data that the FDA requested to stay sealed for 75 years. Well, they lost that lawsuit and in January 2022 a federal judge ruled that the FDA must expedite the release of these documents.
Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection Alan C. Kwan 1 , Joseph E. Ebinger 1, Janet Wei1, Catherine N. Le2, Jillian R. Oft2, Rachel Zabner2, Debbie Teodorescu1, Patrick G. Botting1, Jesse Navarrette1, David Ouyang 1, Matthew Driver1, Brian Claggett3, Brittany N. Weber3, Peng-Sheng Chen1 & Susan Cheng 1
This study was done in Los Angeles and Boston in 2022 and involved 284,592 vaccinated patients. Patients received Pfizer (62%), Moderna (31%), or Johnson & Johnson (6.9%) [less than 0.1% received another product such has AstraZeneca or Novavax]. They compared medical diagnoses that occurred within 90 days after vaccination compared to the 90 days before vaccination. The three diagnoses that had the highest post-vaccination odds were myocarditis, dysautonomia, and POTS.
Myocarditis risk increased by 157% [OR 2.57 (95% CI: 1.02-6.77, p = 0.046)].
Dysautonomia risk increased by 124% [OR 2.24 (95% CI: 1.30-3.87, p = 0.002)].
POTS risk increased by 52% [OR 1.52 (95% CI: 1.36-1.71, p < 0.001)].
Note the gender differences. Myocarditis was more common in males. POTS was more common in females.